News

DRSS stable/improved with OKT-TKI; drug well tolerated

ARCATUS or ARVN001 was developed by Clearside Biomedical and commercialised in the Asia-Pacific region by Arctic Vision

ARCATUS or ARVN001, in Greater China, South Korea, Australia, New Zealand, India and the ASEAN Countries is formally known as XIPERE in the United States and was developed by Clearside Biomedical.

The NPI-001 (N-acetylcysteine amide) tablets are a proprietary investigational therapy for the treatment of patients with retinitis pigmentosa.

Predictive software will use retinal imaging to identify patient risk for Alzheimer and other neurodegenerative diseases

Topline data results are expected in February 2025.

Changes can result in bacterial contamination, loss of drug activity, and inflammation

Following the switch from multifocal to single-vision contact lenses, axial elongation increased by 0.03 mm/year, and myopia progressed at a rate of −0.17 D annually after switching to single-vision lenses.

The study findings suggest that patients should be educated about adherence to cold storage guidelines

Home-stored anti-VEGF drugs face risks from temperature changes, pointing to a need to protect efficacy and avoid dangerous contamination.

Linsitinib is being evaluated in patients with active, moderate to severe thyroid eye disease (TED).

The updated device is designed to meet market diagnostic needs, including within geographic atrophy research

Andrew G. Lee, MD, and Drew Carey, MD, return for this latest episode of the NeuroOp Guru to discuss whether a dead nerve can swell, focusing on the condition of papilledema caused by elevated intracranial pressure.

The iDose platform is designed to address ubiquitous patient non-adherence and chronic side effects associated with topical medications by providing 24/7 release of medication.

RayTrace has been utilized globally by surgeons since 2008.

The transferrin vectorised therapy is being investigated for use in patients with dry age-related macular degeneration and geographic atrophy

Autonomous, AI-based screening consistently resulted in more patients screened with greater cost savings, investigators said

They report a case of endophthalmitis and undertook a literature review to identify previous infections with this pathogen.

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal injection in 3 cohorts.

A case report highlights the pathogen’s potential to cause severe, devastating ocular infections, despite aggressive treatment

In the 5 patients with bilateral geographic atrophy (GA) who received a K8 implant in 1 eye, there was a mean reduction in GA lesion growth of 66% at 3 months.

Cost among other factors may deter patients from screening, especially in rural and low-resource settings.

The company's lead product candidate Duravyu (vorolanib intravitreal insert), f/k/a EYP-1901, is anticipating topline data from several clinical trials in 2026.

The transferrin vectorised therapy is being investigated for use in patients with dry age-related macular degeneration and geographic atrophy

The trial evaluated ONS-5010 in wet age-related macular degeneration patients, and the company plans to resubmit a Biologics License Application in the first quarter of 2025.

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration.